Results for patency translation from English to Maltese

patency
patenza

the patency of the in-dwelling cannula should be tested before injection.
il-kondizzjoni tal-kannula mqegħda għandha tkun eżaminata qabel kull injezzjoni.

attention to airway patency and supportive management of ventilation and haemodynamics are usually sufficient.
attenzjoni li l-passaġġ tal-arja jinżamm miftuħ u ġestjoni ta’ appoġġ tal-ventilazzjoni u tal-emodinamika normalment huma suffiċjenti.

- congenital heart disease in which patency of the ductus arteriosus is necessary for satisfactory
- mard tal- qalb konġenitali li fih il- patency ta ’ ductus arteriosus huwa meħtieġ għall- ċirkolazzjoni

the stroke volume measurement procedure tests pump function, while a catheter flush procedure tests catheter patency.
il-proċedura tal-kejl tal-volum mitfugħ ’il barra tittestja l-funzjoni tal-pompa, filwaqt li l-proċedura tat-tlaħliħ tal- pompa tittestja li m’hemm l-ebda sadda fil-pompa.

coronary patency and limited clinical outcome data showed that ami patients have been successfully treated later than 6 hours after symptom onset.
il-ftuħ koronarju u l-informazzjoni limitata dwar ir-riżultat kliniku wera li l-pazjenti ami kienu kkurati b’suċċess iktar minn 6 sigħat wara l-bidu tas-sintomi.

examination of the patency of the intrathecal catheter should be considered if the required ziconotide dose continually increases and there is no benefit or increase in adverse reactions.
l- eżami tal-ftuħ tal-kateter ġot-teka għandu jiġi kkunsidrat jekk id-doża meħtieġa ta’ ziconotide tiżdied kontinwament u ma jkun hemm l-ebda benefiċċju jew żieda fir-reazzjonijiet avversi.

treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of seizures.
it-trattament ta’ avvelenament b’cyanide jrid jinkludi attenzjoni immedjata għall-ftuħ tal- passaġġ tan-nifs, ossiġinazzjoni u idratazzjoni adegwati, sapport kardjovaskulari u l- immaniġġjar tal-puplesiji.

the patency of the in-dwelling cannula should be tested before injection and every precaution taken against extravasation (see section 4.4).
il-kondizzjoni tal-kannula mdaħħla fil-vina għandha tkun eżaminata qabel kull injezzjoni u għandha tittieħed kull prekawzjoni kontra l-estravażjoni (ara sezzjoni 4.4).

evarrest must not be used to treat severe bleeding from large defects in large arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of evarrest to blood flow and/or pressure during healing and absorption of the product.
evarrest m’għandux jintuża biex isewwi l-ġrieħi kbar fl-arterji jew vini l-kbar sabiex titwaqqaf emorraġija severa fejn il-ħajt vaskulari mġerraħ jeħtieġ tiswija bil-manutenzjoni tal- kondizzjoni tal-vażi tad-demm u li jista’ jirriżulta f’espożizzjoni persistenti tal-evarrest għall-fluss tad-demm u/jew il-pressjoni waqt il-fejqan u l-assorbiment tal-prodott.

patency data from the phase i and ii angiographic studies suggest that tenecteplase, administered as a single intravenous bolus, is effective in dissolving blood clots in the infarct-related artery of subjects experiencing an ami on a dose related basis.
informazzjoni dwar il-ftuħ minn fażi i u ii ta’ l-istudji anġjografiċi tissuġġerixxi li tenecteplase, mogħti bħala bolus wieħed ġol-vina, hu effettiv biex iħoll l-emboli tad-demm f’arterji relatati ma’ l- infart ta’ pazjenti li jkunu jbatu minn ami fuq bażi relatata mad-doża.

in two clinical trials aiming primarily at coronary artery patency (rapid i and ii) reteplase was associated with higher early patency rates (primary efficacy criterion), as well as with a lower incidence of heart failure (secondary efficacy criterion) than alteplase (3 hour and "accelerated" dosage regimens).
f’żewġ provi kliniċi bl-iskop ewlieni tal-ftuħ ta’ arterja koronarja imblukkata (rapid i u ii) reteplase kien assoċjat ma’ rati għola ta’ ftuħ tal-bidu (kriterju primarju ta’ l-effikaċja), kif ukoll ma’ inċidenza aktar baxxa ta’ attakki tal-qalb (kriterju sekondarju ta’ l-effikaċja) minn alteplase (kors ta’ 3 sigħat u dożaġġ "aċċelerat").